UPDATE: Connect Biopharma's Interim Topline Data from Phase 2 Study Shows Rademikibart Reduced Treatment Failure Rate At 28 Days By 66% (Though This Endpoint Did Not Reach Statistical Significance) And Improved Lung Function Vs. Placebo
Share
Why It Matters
Connect Biopharma's new drug helped patients more than a dummy pill did. The help was real, but the test numbers were not solid proof yet.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.